Search

everythinglearnresearchcommunity

for

Search:↓

The user has tried various hair loss treatments including topical minoxidil, oral finasteride, oral dutasteride, oral minoxidil, and exosome therapy, but none have been effective. They suspect trichodynia might be preventing these treatments from working.

Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.

The conversation discusses the use of autologous exosomes for hair loss, questioning their effectiveness and seeking real user experiences. The user is skeptical about the treatment's legitimacy and is looking for honest feedback on its results.

The conversation is about a user who experienced negative side effects and poor sleep after using an impure hair loss treatment 'CB' from Wuhan Hengheda Pharm, which did not offer a refund or proper customer service. The user had the product tested, confirming its impurity.

The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.

Exosomes, cetirizine, melatonin, latanoprost, and caffeine are discussed as potential hair loss treatments. There is skepticism about the effectiveness of exosomes, especially in topical form, but some users report positive results.

The conversation discusses the appearance of hair transplants immediately after surgery, noting that scars will be covered as hair grows. The original poster underwent both FUT and FUE procedures.

The conversation discusses the benefits of combining scalp stem cell treatments and exohealer with RF microneedling before a hair transplant. The original poster recommends these treatments for better results.

Exosome stem cell treatment for hair loss, which is expensive and reportedly effective, but its popularity has declined. The conversation also mentions Minoxidil, finasteride, and RU58841 as treatments.

HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.

New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.

A user is joining a clinical trial for Clascoterone, a drug approved for acne but being tested for hair loss. They previously tried finasteride with limited success and plan to share updates on their experience with the new treatment.

The conversation discusses using intravenous delivery of exosomes for hair growth. It mentions treatments like Minoxidil, finasteride, and RU58841.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

The conversation discusses the use of finasteride for hair loss, comparing every day (ED) versus every other day (EOD) dosing. It suggests that both dosing schedules can be effective, but individual tolerance may vary.

Exosomes are not effective for long-term hair regrowth, with users reporting temporary improvements or no noticeable change. Effective treatments include Dutasteride, Finasteride, Minoxidil, and RU58841, with other options like CB-03-01 and Fluridil offering limited benefits.

Trying out a new exosome treatment for male pattern baldness, in addition to increasing vitamin intake and using existing treatments such as Nizoral and scalp drops. The user has no expectations that the new treatment will work but is giving it a try anyway.

A 23-year-old male has been experiencing hair loss since 2022 and has used minoxidil and dutasteride with reduced shedding but no hair regrowth. He is considering PRP with mesotherapy and red light therapy, GFC, or exosomes, with a preference for exosomes due to efficiency and a reputable clinic.

Exosome treatment for hair loss is being considered, but its effectiveness is questioned. The user is already using finasteride and minoxidil and is contemplating a hair transplant.

ET-02 showed significant hair growth in five weeks, outperforming minoxidil, with a non-hormonal mechanism that avoids side effects of treatments like finasteride. A phase 2 trial is planned to further assess ET-02's efficacy and safety.

Hair loss discussion includes PRP and exosomes treatments. Questioning effectiveness and ideal candidate for these treatments.

A 22-year-old with high estradiol levels is considering starting finasteride for hair loss. They have an upcoming endocrinologist appointment to discuss whether they should proceed with the treatment.

A European individual planning to go to China is seeking information on how to participate in HMI-115 trials for Androgenetic Alopecia. They've tried contacting Mrs. Yang and Mr. Wang for assistance but haven't received a response.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

The potential availability of a new hair loss treatment called HMI-115, which has shown promising results in experiments on monkeys but is not yet available to the public. Replies cautioned against using unproven substances from shady labs.

The conversation discusses the importance of Finasteride for hair loss treatment in the EU and encourages individuals to voice their support to the EMA. It highlights the potential influence of public input on regulatory decisions.

Hyperbaric Oxygen Therapy (HBOT) is discussed as a potential treatment for androgenic alopecia due to its ability to reverse hypoxia and promote angiogenesis. The conversation explores its potential benefits for hair loss, though no studies have been conducted on this application yet.

The conversation discusses a new hair growth treatment that showed a 14 hairs/cm2 increase in a trial, with mixed opinions on its effectiveness and potential cost. Some users are hopeful about combining it with existing treatments like oral minoxidil for better results.

The conversation discusses HMI-115, a potential cure for hair loss. Users share mixed opinions, with some expressing skepticism and others sharing anecdotal evidence of its effectiveness, including photos of significant hair regrowth from a trial participant.

The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.